HC Wainwright & Co. Maintains Buy on Caribou Biosciences, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns maintains a Buy rating on Caribou Biosciences (NASDAQ:CRBU) but lowers the price target from $24 to $9.
June 04, 2024 | 10:13 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
HC Wainwright & Co. analyst Robert Burns maintains a Buy rating on Caribou Biosciences but significantly lowers the price target from $24 to $9.
The significant reduction in the price target from $24 to $9 suggests a more cautious outlook on the stock's potential, which could lead to a negative short-term impact on the stock price despite the maintained Buy rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100